Open · RFA-NS-26-001 · CFDA 93.853 · Discretionary
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- Varies
- Award range
- Open
- Status
- 17d
- Days left
- 4
- Expected awards
The verdict
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) is an open discretionary opportunity from National Institutes of Health, offering Varies by applicant across 4 expected awards. Applications close in 17 days. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.
- Varies
- award range
- Open
- 17 days left
- 4
- expected awards
- 93.853
- CFDA program
Tight application window
Amyotrophic Lateral Sclerosis (RFA-NS-26-001) closes in 17 days on November 10, 2026. Award band Varies by applicant across 4 expected awards. National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Validate SAM.gov registration before drafting; amendments on Grants.gov can move the deadline.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
17 days left to apply
Posted May 4 → closes Nov 10, 2026
Est. Total Funding
$40,000,000
Expected Awards
4
Instrument
Cooperative Agreement
Description
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products as described in section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb). These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not eligible for ongoing clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS.
Wide-open applicant board · 15 Grants.gov doors
Amyotrophic Lateral Sclerosis prints 15 distinct Grants.gov eligibility doors (State governments; County governments; City or township governments; Special district governments; +11 more). Filter fit before reading award size as demand — most applicant classes appear on the row. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity code maps to Health (HL). This eligibility-code string dominates the National Institutes of Health book (9,741 peers, 78% of 12,420).
- Code 00
- State governments
- Code 01
- County governments
- Code 02
- City or township governments
- Code 04
- Special district governments
- Code 05
- Independent school districts
- Code 06
- Public / state-controlled institutions of higher education
- Code 07
- Federally recognized tribal governments
- Code 08
- Public / Indian housing authorities
- Code 11
- Native American tribal organizations (other than Federally recognized tribal governments)
- Code 12
- Nonprofits with 501(c)(3) status (other than IHEs)
- Code 13
- Nonprofits without 501(c)(3) status (other than IHEs)
- Code 20
- Private institutions of higher education
- Code 22
- For-profit organizations other than small businesses
- Code 23
- Small businesses
- Code 25
- Others (see official listing text)
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
ALS Program NINDSALSMailbox@mail.nih.gov
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
What to do next
Amyotrophic Lateral Sclerosis is open with Varies by applicant awards and 17 days left on the clock.
- Submit through Grants.gov (RFA-NS-26-001) - verify SAM.gov registration and the current NOFO before drafting. Official listing
- Look up CFDA 93.853 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |